Study guide
4.3 EPA, OSHA, HIPAA, FDA, and USP Standards
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
4.3 EPA, OSHA, HIPAA, FDA, and USP Standards
Key Takeaways Explain This Topic AI
EPA rules address environmental releases and radioactive waste pathways beyond the clinic’s NRC license boundaries
OSHA bloodborne-pathogen and hazard-communication standards require PPE, sharps safety, exposure plans, and chemical labeling in the NM workplace
HIPAA Privacy and Security Rules protect patient identifiers, images, reports, and electronic PHI handled by technologists
FDA regulates radiopharmaceuticals as drugs and oversees related devices/manufacturing quality (including PET drug expectations)
USP <797> sets sterile compounding principles; USP <825> provides radiopharmaceutical-specific preparation, compounding, dispensing, and repackaging standards used with institutional SOPs and accreditation
Last updated: August 2026
NRC medical-use rules and DOT shipping (Sections 4.1–4.2) do not cover every Domain II question. Patients still bleed, chemicals still splash, records still identify people, and radiopharmaceuticals are still drugs prepared under pharmacy-quality expectations. Technologists also work under EPA, OSHA, HIPAA, FDA, and USP frameworks—implemented through hospital SOPs and accreditation .
EPA — Environmental Waste and Releases
The Environmental Protection Agency (EPA) addresses environmental protection for radioactive material pathways that leave simple “inside the hot lab” control:
Waste leaving institutional control must use authorized routes (licensed burial, approved incineration, permitted effluent)—not improvisation.
Air and water effluents (stacks, sewers) face concentration and dose criteria tied to environmental goals and NRC license conditions.
“Dilute and dump” without calculation and documentation fails both NRC and environmental expectations.
For NMTs: respect decay-in-storage vs brokered waste , never bypass xenon/iodine trap systems, and escalate unusual environmental releases to the RSO. You need not recite every EPA numeric table, but you must know who owns the problem when waste or effluent leaves incorrectly.
OSHA — Worker Safety Beyond Badges
OSHA protects employees from workplace hazards beyond pure radiation dosimetry:
OSHA focus Nuclear medicine examples
Bloodborne pathogens (29 CFR 1910.1030) IVs, blood labeling (RBC/WBC), fingersticks, sharps, contaminated gloves
- Hazard communication Kit reagents, solvents, disinfectants, PET cryogens, cleaners
- PPE Gloves, gowns, eye/face protection for splash risk
- Sharps safety Engineered sharps, no hand recapping, containers at point of use
Bloodborne pathogen programs include an exposure control plan, standard precautions, hepatitis B vaccination offers, post-exposure evaluation, and training. A needlestick after blood labeling is an OSHA exposure incident (and infection-control event)—not only a radiation survey issue, even if the blood was radioactive.
PPE is task-based: gloves for every unsealed manipulation; gown when splash is likely; eye protection when drawing/spiking under pressure. Syringe shields cut dose ; gloves address contamination and biohazard . SDS access is expected; “we only worry about millicuries” fails after a reagent injury.
HIPAA — Privacy and Security
HIPAA Privacy and Security Rules govern protected health information (PHI) in nuclear medicine:
- Names, MRNs, birth dates on requisitions and dose labels
- Images, reports, and worksheets
- Hallway conversations and visible workstation screens
- Schedules left on public counters
Privacy Rule: use/disclose only the minimum necessary PHI for treatment, payment, operations, or other permitted purposes; verify identity before releasing results.
Security Rule: protect electronic PHI with access controls, unique logins, workstation policies, and safeguards against lost media or unlocked PACS stations.
Classic failures: posting a patient’s diagnosis on social media; elevator therapy gossip; emailing identifiable images to a personal account; leaving a WD printout on a public printer. Radiation safety culture and privacy culture are parallel duties.
FDA — Drugs, Devices, and Product Quality
The FDA regulates radiopharmaceuticals as drugs (and many related devices ):
Commercial diagnostic and therapeutic RPs are approved products with labeled indications, activity ranges, and handling.
Investigational agents require IND/protocol pathways—do not freestyle unapproved mixtures.
PET drugs and institutional production carry manufacturing quality expectations: identity, purity, sterility, documentation.
Ancillary drugs (e.g., pharmacologic stress agents) remain FDA-regulated medications.
Imaging equipment may fall under device rules and manufacturer QC expectations.
FDA does not replace NRC licensing, but perfect wipe logs do not excuse an expired, misbranded, or improperly compounded product.
USP <797> and USP <825>
USP <797> sets sterile compounding standards to protect patients from microbial contamination, endotoxins, and dosing errors (hygiene, engineering controls, beyond-use dating, aseptic technique).
USP <825> covers radiopharmaceuticals—preparation, compounding, dispensing, and repackaging , recognizing shielding, dose calibrators, and decay time pressure:
- Topic Practice implication
- Aseptic technique Critical for kits, dilutions, and blood labeling
- Segregation Radioactive vs nonradioactive; dirty vs clean steps
- Beyond-use / expiration Honor manufacturer/pharmacy times; decay ≠ longer sterility
- Environment Follow institutional hot-lab / hood / isolator rules
- Documentation Who prepared what activity, lot, and time
<825> is RP-focused; <797> is the broader sterile backbone. Sites map both into nuclear pharmacy SOPs. Kit reconstitution, dilutions, and blood labeling are compounding-adjacent work—not “just injecting.”
Institutional SOPs and Accreditation
Regulations state what must be achieved; SOPs state how this hospital does it —spills, WD checks, package receipt, generators, pregnancy screening, PPE, HIPAA workstations, waste. Inspectors (NRC/agreement state, pharmacy boards, The Joint Commission , ACR / IAC where applicable) test whether practice matches procedure.
Expect documented competencies, annual radiation safety training, therapy timeouts, multi-channel incident reporting (radiation, medication, HIPAA, sharps), and equipment QC aligned with accrediting checklists. When habit conflicts with SOP or license conditions, written procedure wins until formally revised.
One Scenario, Many Agencies
Preparing a Tc-99m labeled blood product engages:
- NRC/license: possession, surveys, waste, personnel dose
- USP <825>/<797>: aseptic labeling and documentation
- FDA: component/product quality expectations
- OSHA: bloodborne PPE and sharps
- HIPAA: identifiers on labels and worksheets
- EPA/NRC waste rules: contaminated blood waste disposition
- SOP/accreditation: the checklist you sign
- Exam Hooks
Needlestick during RBC labeling → OSHA bloodborne (+ radiation survey if activity present).
PHI on an unlocked public workstation → HIPAA .
Expired compounded sterile RP administered → USP/FDA quality issue.
Unauthorized sewer disposal of concentrated long-lived waste → EPA/NRC environmental violation.
Skipping the hospital therapy checklist that implements the WD → SOP failure that can become a medical event.